Leiden, Netherlands

Ariane Rodriguez-Munoz

This inventor holds 1 USPTO granted patent. Top assignee: Crucell Holland B.v.. Active years: 2015.


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Malaria Vaccination by Ariane Rodriguez-Munoz

Introduction

Ariane Rodriguez-Munoz is an accomplished inventor based in Leiden, Netherlands. She has made significant contributions to the field of immunology, particularly in the development of vaccination regimens against malaria. Her innovative approach aims to enhance the immune response to malaria-causing parasites.

Latest Patents

Ariane holds a patent for a "Heterologous prime boost vaccination regimen against malaria." This patent describes methods for inducing an immune response in a subject against an antigen from a malaria-causing parasite. The method involves administering a priming composition that includes an adjuvanted proteinaceous antigen-comprising circumsporozoite (CS) protein. It also includes two boosting compositions using recombinant adenovirus vectors that encode the CS protein or its immunogenic parts.

Career Highlights

Ariane is currently associated with Crucell Holland B.V., where she continues her research and development efforts. Her work focuses on creating effective vaccination strategies to combat malaria, a disease that poses a significant health threat in many parts of the world.

Collaborations

Ariane collaborates with notable colleagues, including Katarina Radosevic and Angelique Alida Corina Lemckert. These collaborations enhance the research efforts and contribute to the advancement of malaria vaccination strategies.

Conclusion

Ariane Rodriguez-Munoz is a pioneering inventor whose work in malaria vaccination is making a difference in global health. Her innovative approaches and collaborations are vital in the fight against malaria.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…